Orris

I am a first-year medical resident in MD Medicine. I daily get many cases of hepatitis B and hepatitis C. I want to get beautiful notes and handouts for the screening, treatment, and prevention of hepatitis B and C so that I can effectively treat my patients on a daily wards and OPD basis and for surveillance. You give me notes and specially give me mnemonics for different types of treatments or etiology basis or wherever needed. Answer according to the latest guidelines and clinical evidences , textbooks

Reading File
Finding Sources
Finding Sources
Searching PubMed

"hepatitis B" AND "treatment guidelines"

Searching PubMed

"hepatitis C" AND "direct acting antiviral" AND "guidelines"

Searching the Web

AASLD EASL hepatitis B C treatment guidelines 2025 2026 latest update

Reading File
Reading File
Reading Web Page

hepatitis B screening treatment prevention guidelines 2025

Finding Sources
Reading File
Finding Sources
Searching PubMed

"hepatitis C" AND "pangenotypic" AND "treatment"

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Here's a summary of what your handout covers and how to use it on the wards:

How to Use This Handout

On Ward rounds:
  • Jump to the "WHO TO TREAT" table (Part 1, Section 4) for instant HBV treatment decisions
  • Use the "SCA Triad" result interpretation table to decode any serology report in 30 seconds
  • The HBV phases table (IT → IH → IC → Cure) explains your patient's current status
In OPD:
  • Use the AASLD 2025 triple panel screening algorithm for every new patient with risk factors
  • For new HCV diagnoses: Anti-HCV → HCV RNA → Genotype → pick regimen from the DAA table
  • The "8-12-16-24 rule" tells you treatment duration at a glance
For counseling:
  • "CHAIR" mnemonic for HCC surveillance eligibility
  • "3-V-P" for HBV prevention counseling
  • "SHARP" for HCV harm reduction

Key 2025 Updates You Must Know

  1. HBV immune-tolerant phase - AASLD 2025 now recommends treating if HBV DNA ≥10,000 IU/mL regardless of ALT - this is a major shift from prior "watch and wait" for immune-tolerant patients.
  2. qHBsAg <100 IU/mL is an emerging threshold for considering NUC discontinuation in selected HBeAg(-) non-cirrhotic patients.
  3. GLE/PIB (Glecaprevir/Pibrentasvir) achieves ~99% SVR in just 8 weeks for treatment-naïve non-cirrhotic HCV patients of all genotypes - the shortest curative regimen available.
  4. HBV/HCV co-infection during DAA therapy risks HBV reactivation (sometimes fatal) - always screen triple panel before starting DAAs.
  5. Bulevirtide is now approved for chronic HDV (hepatitis delta) in HBsAg(+) co-infected patients - ask about HDV testing in your South Asian/Mediterranean/IVDU HBV patients.
This is a shared conversation. Sign in to Orris to start your own chat.